Introduction
In the risk assessment of medicines and chemical agents, bioassays using several experimental animals are conducted 1,2. However, accounting for the species difference between humans and experimental animals when extrapolating human response from animal data is difficult3,4.
In general, the species difference consists of anatomical and functional differences, and the most critical one affecting toxicological responses is the metabolism of the agents5. Thus in vitro studies using human liver cells and microsomes are becoming popular in the toxicological field6,7. However, quite often results from human liver specimens are inconsistent, because the background of each specimen varies significantly. On the other hand, with the rapid development of molecular biology, transgenic yeast8, cultured cells9, and mice10 harbor ing human genes of drug-metabolizing enzymes have been produced for predicting the human response to chemicals. In the present study of the response of human glutathione S transferase (GST) to chemical inducers, transgenic rats which harbor 4.5kb of human GST alpha 1 promoter region in their genome were exposed to several well-known inducers.
Materials and Methods

Animals
Transgenic rats carrying the 4.5-kb 5'-flanking promoter region of the human GST alpha 1 (A1) gene fused to a chloramphenicol acetyltransferase (CAT) reporter gene ( Fig.  1) were generated at the YS New Technology Institute Inc. (Tochigi, Japan). The transgenic rats were screened by the Fig. 1 
Results
Measurement of liver drug-metabolizing enzymes
The results of P450 contents and activities of ACD, UDP-GT, and GST in the liver of Tg-GSTAI rats are shown in Table 1 . In the PB treatment group, significant increases were observed in all the examined parameters, i.e., P450 content and ACD activities involved in MCD, ECD, and PCD reached approximately 200% or more of the control value, and activities of UDP-GT and GST-C reached 150 and 137% of the control values, respectively. In the BNF group, significant increases were observed in activities of ECD, PCD, and UDP-GT (486, 327, and 252% of the control values, respectively), whereas no significant changes were detected in MCD, GST-C or GST-D.
In the BHA treat ment group, phase II enzymes, UDP-GT, GST-C, and GST D, significantly increased (376, 192, and 160% of the control values, respectively). Phase I enzyme was not induced by BHA.
CAT assay
The results of the CAT assay are shown in Table 2 . Tg-GSTAI rat liver was used as the control for CAT protein. The amounts of CAT protein in the BNF and BHA treat ment groups were comparable to that in the control group. However, the amount of CAT protein in the PB treatment group was significantly increased and reached 148% of the control value.
Immunohistochemistry for CAT protein
In the control Tg-GSTAI rats, CAT protein was demonstrated immunohistochemically in several layers of liver cells around the central vein (Fig. 2) . The same findings were obtained in the livers from the BNF and BHA treatment groups. In the PB treatment group, centrilobular distribution of CAT protein was also demonstrated, however, the distribution was widened from the central vein to the mid-zone of the lobule compared with that of the other treatment and control groups (Fig. 3) .
Discussion
It has been demonstrated that a lot of chemicals exert inductive effects on liver drug-metabolizing enzymes in several animal species16,17 However, few studies using human enzymes have been conducted18, because of the difficulty in examining human liver specimens.
This led us to develop a line of transgenic rats carrying a human GSTAl promoter gegion to predict the response of human GST to chemical inducers.
In the present study, we used 3 chemical inducers, which have clearly different types of induction profiles, PB, BNF, and BHA, in the Ta-GSTAI rats.
As a result, constitutive rat liver enzymes, i.e., P450, GST, and UDP-GT, were induced in different ways depend ing on the inductive properties of each of the three chemicals used. These induction profiles were consistent with those reported for non-Tg rats19. Thus it was demonstrated that the present Tg-GSTAI rats responded to chemical inducers in the same manner as non-Tg rats, and the injected gene did not affect the expression of the constitutive rat liver enzymes.
The response of human GSTAI gene to chemicals was evaluated by the change of transcription activity in the promoter region, which can be determined by the expression level of CAT protein in rat liver tissues. Expression of CAT protein was demonstrated in the control Tg-GSTAI rats, indicating the gene expression in the rat liver cells. In addition, the expression level was significantly increased only in the rats treated with PB. This indicated that the injected GSTAI promoter responded to PB, and accordingly suggest Nevertheless, it also must be taken into account that the negative results observed in th the the BNF and BHA treatment groups might not directly reflect the response of human GST to the chemicals. It is possible that the 4.5-kb 5'-flanking promoter region of the human GSTAl gene, injected into the present Tg rats, was not appropriate for responding to the chemicals, though the region responded to PB. Further study is needed to obtain conclusive results.
In conclusion, Tg rats harboring human genes are con sidered useful for predicting the response of human genes to chemicals, based on the present results.
Therefore, Tg ani mal models will be used much more extensively in the near future, though the results must be carefully evaluated from a critical point of view. 
